Case Study #3: A Case Study of Paxlovid Rebound Patient

Case Study #3: A Case Study of Paxlovid Rebound Patient

Symptoms Include: Fatigue, Tinnitus, Insomnia, Brain Fog, Fever, Joint Pain, Gastrointestinal Issues, Shortness of Breath, and Changes in Libido

A 30-day case study by Dr. Lee Morgentaler of a 3CL protease cleanse with Tollovid, a 3CL protease inhibitor dietary supplement, in a patient who experienced Long Haulers Rebound following intervention with Pfizer’s Paxlovid.

Acute Sequelae of SARS-CoV-2 (PASC), also known as "Long Haulers", is a major public health problems. Emerging evidence suggests the PASC, for many, may in fact be due to persistent SARS-CoV-2 infection that is able to evade vaccine or infection-induced immunity and cause recurring and persistent symptoms. PASC does not appear to protect against new acute SARS-CoV-2 infection, and PASC may in fact contribute to poor outcomes in new acute infections and/or recurrent symptoms from prior infection.

Todos Medical reports a case of a patient with a history of multiple SARS-CoV-2 infections and persistent PASC, who received the therapeutic intervention Paxlovid following a positive PCR test and experienced severe rebound of symptoms starting on Day 5, the final day of Paxlovid treatment. The patient’s symptoms were resolved following an initial 14-day cleanse with 3CL protease inhibitor immune support dietary supplement Tollovid®.

SUMMARIZED CASE REPORT:
A 53-year-old female in excellent physical condition experienced four COVID-19 infections over the course of two years between March 13, 2020 through April 20, 2022.  The patient is a single mother with a son in college and lived a very reclusive lifestyle.  Her current blood panels suggest that she is now immunocompromised.  Before the first COVID-19 infection on March 13, 2020 the patient did 3 to 6 miles of daily trail running four times per week.  She also taught school three times per week and cycled the 8-mile distance to work each time.  She was 5 ft 6 in, 160 lb, had a resting pulse rate of 60, and had all blood work within normal limits.  At the time immediately prior to beginning intervention with Tollovid in this case study she weighed 185 lb, her blood work was abnormal, and she was experiencing vision problems and gastrointestinal issues that resulted in the removal of her gall bladder.  From March 13, 2020 to April 20, 2022 she experienced 13 trips to the Emergency Room.

In March 2020, after isolation for a week the patient presented COVID-19 symptoms of elevated heart rate, shortness of breath, GI tract issues, difficulty breathing, and what the patient describes as debilitating body spasms.  These symptoms were so severe that the patient had to be transported to the hospital by ambulance. 

In May 2020, after experiencing worsening symptoms the patient checked into Rust Medical Center in Rio Rancho with excruciating abdominal pain.  A cholecystectomy was performed on an emergency basis.  The GI symptoms subsided after surgery.  During that hospital stay she tested negative on a nasal PCR test. 

A fecal COVID test was done in July 2020.  The first fecal test was negative for COVID but the patient was not having any symptomatic issues related to the GI tract. The patient remained in complete isolation for the next couple of weeks and then had a GI flare up when the second test was completed.  This fecal COVID test was COVID-19 positive.  The patient eventually recovered and returned baseline and was able to run up to six miles again.  

In February 2021, the patient received the first in a series of two Pfizer vaccination shots.  The patient tolerated the vaccinations without any side effects.

The next infection occurred in June 2021 shortly after the patient broke a 4-month long isolation.  The patient broke isolation to meet travelers who were only wearing cloth masks for protection while driving an hour in the car.  The patient started showing symptoms within 2 days after potential exposure.  These symptoms included elevated heart rate, fever up to 101, pain in the chest, insomnia, swollen veins, loss of appetite, red eyes, trembling, pulse oximeter reading of 93% to 94%, and diarrhea.  She took over-the-counter electrolytes, vitamin C&D, iron supplements, and resveratrol.  Recovery took 3 weeks and the patient was able to resume long walks and her temperature normalized. 

Despite the patient’s diligence in practicing self-isolation, thereafter she was exposed to a person who took off their mask.  At the time the patient was wearing a cloth mask.  Within two days of the exposure the patient was infected for the 3rd time and remained sick for at least a month.  The patient tested COVID-19 positive on August 24, 2021 by a lateral flow antigen test.  The symptoms manifested more in her eyes, nasal passage, and auditory system.  Symptoms included ringing in the ears and double vision.

On December 15, 2021, the patient removed her P100 mask and airtight goggles during a medical exam and then presented symptoms of COVID-19 within 3 days.  The patient tested COVID-19 positive via rapid antigen test on December 18, 2021.  The patient exhibited signs of Long COVID which include fever, tremors, headaches, diarrhea, and shortness of breath. These symptoms continued to persist until April 8, 2022.

On April 1, 2022, the patient started taking prednisone to treat her red swollen hands, vasculitis, and easy bruising.  On April 8, 2022, the patient started showing signs of COVID and took a PCR rapid test which showed a faint positive reading.  On April 14th, her doctor prescribed a 5-day course of Paxlovid.  Within hours the patient was symptom free.  She was able to clean the house and felt so well she went on a four-mile hike. She also noticed that this was the first time she was able to sleep through the night in two years.  The patient also did voiceovers, and her voice came back briefly during this period.  On the 5th day of Paxlovid treatment she saw a return of her symptoms.  She became bedridden on day 5 with shaking, tremors, 101 fever, and claylike feces.  On April 19th the patient still tested COVID-19 positive. 

On April 21, 2022, the patient started a regimen of Tollovid.  She took three capsules four times a day for 14 days. Her symptoms began to resolve within 24 hours and continued to improve for ten days.  The patient is awaiting results of a complete blood panel.  However, on May 4, 2022, she tested COVID-19 negative via NP/OP swab resulted on rtPCR.  Additionally, a C-Pass neutralizing antibody test was performed indicating 94.731% inhibition with titers greater than 6000 u/ml.  The patient reported that as of three days ago all her symptoms were resolved.  She attributes this recovery to the treatment with Tollovid. The patient plans on continuing to take two capsules of Tollovid twice a day for the next 14 days. 

DISCUSSION:
This case study reveals that the patient responded to 3CL protease inhibitors Paxlovid and Tollovid.  Tollovid acted as an excellent rescue agent for Paxlovid failure in Long COVID or COVID-19.  The patient observed relief in hours using both treatments.  The patient was fully vaccinated and it didn’t prevent infection. 

Back to blog